Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur Roberto D'ALESSANDRO

📍 Paris 14e Arrondissement (75)HospitalierRPPS 10109462852
📊 Reconnaissance scientifique : 27/100📝 111 articles publiés

Diplômes

🎓 DES & spécialité ordinale

  • Rhumatologie (SM)

🎓 Diplômes

  • Diplôme éq d'un pays de l'EEE profession Médecin

📝 Autres formations

  • DEES Rhumatologie

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Activité de recherche & publications

Source : bases de données publiques (OpenAlex, PubMed).

h-index

27

h articles cités ≥ h fois chacun. Un h de 27 = 27 publications avec 27+ citations.

Citations

2 156

Publications

111

i10-index

51

Thématiques principales

  • Migraine and Headache Studies ×10
  • Systemic Sclerosis and Related Diseases ×9
  • Multiple Sclerosis Research Studies ×8
  • Rheumatoid Arthritis Research and Therapies ×8
  • Spondyloarthritis Studies and Treatments ×8

Affiliations FR : Inserm · Université Paris Cité · Hôpital Cochin

Voir sur OpenAlex ↗🆔 ORCID 0000-0002-8350-7581

Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.

Lieu de consultation

  • GHU APHP CUP SITE COCHIN PORT ROYAL

    27 Rue DU FAUBOURG SAINT JACQUES, 75679 Paris 14e Arrondissement

    ☎ 0158414141Hospitalier

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network

    Journal of inherited metabolic disease · 2021

    📚 63 citations🎯 RCR 4.82Top 8% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    AbstractMitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive disease caused byTYMPmutations and thymidine phosphorylase (TP) deficiency. Thymidine and deoxyuridine accumulate impairing the mitochondrial DNA maintenance and integrity. Clinically, patients show severe and progressive gastrointestinal and neurological manifestations. The onset typically occurs in the second decade of life and mean age at death is 37 years. Signs and symptoms of MNGIE are heterogeneous and confirmatory diagnostic tests are not routinely performed by most laboratories, accounting for common misdiagnosis. Factors predictive of progression and appropriate tests for monitoring are still undefined. Several treatment options showed promising results in restoring the biochemical imbalance of MNGIE. The lack of controlled studies with appropriate follow‐up accounts for the limited evidence informing diagnostic and therapeutic choices. The International Consensus Conference (ICC) on MNGIE, held in Bologna, Italy, on 30 March to 31 March 2019, aimed at an evidence‐based consensus on diagnosis, prognosis, and treatment of MNGIE among experts, patients, caregivers and other stakeholders involved in caring the condition. The conference was conducted according to the National Institute of Health Consensus Conference methodology. A consensus development panel formulated a set of statements and proposed a research agenda. Specifically, the ICC produced recommendations on: (a) diagnostic pathway; (b) prognosis and the main predictors of disease progression; (c) efficacy and safety of treatments; and (f) research priorities on diagnosis, prognosis, and treatment. The Bologna ICC on diagnosis, management and treatment of MNGIE provided evidence‐based guidance for clinicians incorporating patients' values and preferences.

  • 2
    Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial

    JAMA neurology · 2018

    📚 50 citations🎯 RCR 3.16Top 15% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
  • 3
    Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism

    Movement disorders : official journal of the Movement Disorder Society · 2021

    📚 44 citations🎯 RCR 3.10Top 15% NIH🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    ABSTRACTBackgroundThe risk of COVID‐19 and related death in people with Parkinson's disease or parkinsonism is uncertain. The aim of the study was to assess the risk of hospitalization for COVID‐19 and death in a cohort of patients with Parkinson's disease or parkinsonism compared with a control population cohort, during the epidemic bout (March–May 2020) in Bologna, northern Italy.MethodsParticipants of the ParkLink study with the clinical diagnosis of Parkinson's disease or parkinsonism and people anonymously matched (ratio 1:10) for sex, age, district, and Charlson Index were included. The hospital admission rate for COVID‐19 (February 26–May 31, 2020) and the death rate for any cause were the outcomes of interest.ResultsThe ParkLink cohort included 696 subjects with Parkinson's disease and 184 with parkinsonism, and the control cohort had 8590 subjects. The 3‐month hospitalization rate for COVID‐19 was 0.6% in Parkinson's disease, 3.3% in parkinsonism, and 0.7% in controls. The adjusted hazard ratio (age, sex, district, Charlson Index) was 0.8 (95% CI, 0.3–2.3, P = 0.74) in Parkinson's disease and 3.3 (1.4–7.6, P = 0.006) in parkinsonism compared with controls. Twenty‐nine of the infected subjects died; 30‐day fatality rate was 35.1%, without difference among the 3 groups. Six of 10 Parkinson's disease/parkinsonism patients had the infection during hospitalization or in a nursing home.ConclusionsParkinson's disease per se probably is not a risk factor for COVID‐19 hospitalization. Conversely, parkinsonism is an independent risk factor probably because of a more severe health status, entailing higher care dependence and placement in high‐infection‐risk accommodations. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal24

▼

Épidémiologie & registres7

▼

Biothérapies non-anti-TNF3

▼

Revue générale3

▼

Case report / série2

▼

Pharmacovigilance2

▼

Revue / méta-analyse2

▼

Sjögren2

▼

Anti-TNF1

▼

Échographie1

▼

Essai clinique1

▼

IRM ostéo-articulaire1

▼

JAK inhibiteurs1

▼

Lupus1

▼

Maladie à IgG41

▼

Pédiatrie1

▼

Qualité de vie / PROMs1

▼

Tendinopathies & SCC1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.